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Abstract
Background: Managing HIV-associated cryptococcal meningitis (CM) can become challenging in the presence of
concurrent unusual central nervous system infections.
Case presentation: A 58-year old HIV infected woman new ART starter, who was being treated effectively for
cryptococcal meningitis, represented with worsening of neurological symptoms. Brain MRI revealed a multicystic
lesion in the left temporal lobe. Anti-fungal treatment was escalated for a suspected cryptococcoma, but post-
mortem CSF serological test confirmed racemose neurocysticercosis.
Conclusion: Patients with HIV-associated CM are highly immunocompromised and may have multiple pathologies
simultaneously. In endemic countries, neurocysticercosis should be considered in the differential diagnosis where
there is central nervous system deterioration despite effective therapy for CM.
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Background
Cryptococcal meningitis (CM) is the most common
neurological complication of advanced immunodefi-
ciency in HIV-infected individuals. In 2014, 250,000 inci-
dent cases were reported and CM accounted for 15% of
AIDS-related deaths [1]. With current antifungal treat-
ments, mortality attributable to CM ranges between 20
and 50% [1, 2]. Despite the scale-up of ART coverage in
sub-Saharan Africa, the numbers of people progressing
to advanced immunosuppression exceed the capacity of
ART programs [3]. Patients with HIV-associated CM re-
main at risk of other opportunistic infections. Managing
CM in HIV-infected patients can become challenging
when other unusual central nervous system infections
occur concurrently. We describe a case of coincidental
racemose neurocysticercosis in a patient being treated
for HIV-associated cryptococcal meningitis, clinically
and microbiologically responding to antifungal therapy.
Case presentation
A 58-year old HIV-infected woman presented with a 3-
day history of headache to Queen Elizabeth.
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Central Hospital (QECH), a teaching hospital in Blan-
tyre, Malawi. The headache was associated with fever,
vomiting, confusion, and loss of consciousness a day be-
fore presentation. She did not report any convulsions or
constitutional symptoms. She had started first-line ART
(Tenofovir, Lamivudine and Efavirenz) two months be-
fore presentation and reported good adherence to treat-
ment. The patient was afebrile and her Glasgow coma
scale (GCS) was 14/15. She had marked neck stiffness,
there was no evidence of focal neurological deficit. Her
baseline CD4 count was 26 cells/μl and serum glucose
was 6.1 mmol/L (normal 4.0 to 7.0 mmol/L). CSF
showed an opening pressure of 23cmH2O (normal range
5 to 15 cmH2O) [4], was positive on a lateral flow assay
(LFA) (IMMY) for cryptococcal antigen (crAg), white
cell count (WBC) 0 cells/mm3 (normal < 5), red cell
count (RCC) 160 cells/mm3 (normal < 10), protein 3.01
g/L (normal 20–40), glucose 2.2 mmol/L (normal range
2.5–4.5). Quantitative cryptococcal culture (QCC) subse-
quently demonstrated 910 colony-forming units (CFU)
per ml. A combination of oral fluconazole 1200 mg once
a day and flucytosine 1000mg 6 hourly was commenced
as part of the ACTA clinical trial (Open-label, multicen-
tre randomized trial; doi: https://doi.org/10.1056/
NEJMoa1710922). She showed a good clinical response
to antifungal treatment with resolution of confusion and
vomiting but required daily lumbar punctures (LP) for
persistent raised intracranial pressure (ICP). By day 14
her clinical symptoms had improved, her ICP normal-
ized and there was no growth on CSF fungal culture.
She was commenced on consolidation therapy with flu-
conazole 800 mg once daily alone and discharged with a
scheduled review in two weeks.
28 days after her initial presentation, she represented
with headache, confusion, and neck pain. She had a new
right-sided upper motor facial nerve palsy. Lumbar
puncture (LP) showed a raised ICP of 28 cmH2O. Serum
glucose was 5.2 mmol/L and CSF analysis showed WBC
0 cells/mm3, RCC 130 cells/mm3, glucose 2.2 mmol/L,
protein 2.61 g/L, and was still positive for crAg (titers
were not available). The QCC, available after five days,
was 700 cfu/ml (previously sterile) and a repeat CD4
Fig. 1 Sagittal T1 Fluid-attenuated inversion recovery (A), Axial T2 (B), and Coronal T2 images (C) were taken 4 weeks after the initial presentation:
showing a 6cmx5cmx6cm multicystic mass lesion in the left temporal lobe with surrounding oedema. It is compressing the lateral ventricles,
causing early hydrocephalus and midline shift to the right. Axial T2 were taken 4 weeks after the initial presentation (D), and 14 days after
retreatment with antifungals and steroids (E): The multicystic mass in the left temporal lobe had increased in size (B) with more surrounding
oedema, progressing obstructive hydrocephalus (B; red arrows), increased midline shift, effacement of basilar cisterns and compression of
the brainstem
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count was 49 cells/μl. Magnetic resonance imaging
(MRI) of her brain demonstrated a 6 cm × 5 cm × 6 cm
multicystic mass lesion in the left temporal lobe with
surrounding edema that was compressing the lateral
ventricles causing early hydrocephalus and a 1 cm mid-
line shift to the right (Fig. 1 A- D). Thigh radiographs
did not show any evidence of spindle-shaped calcifica-
tion. She was treated for suspected CM relapse and
cryptococcoma with intravenous amphotericin B deoxy-
cholate 1 mg/kg and oral fluconazole 1200 mg daily for
14 days according to the Malawi Standard Treatment
guidelines, plus prednisolone 60mg once daily to reduce
the cerebral edema. She was monitored closely as an in-
patient and samples were sent for neurocysticercosis
serological testing in London as they were not available
in Malawi.
After 14 days of treatment, a follow-up MRI of the
brain demonstrated worsening radiological changes: the
mass had increased by 200%, increased edema, increased
midline shift to the right, more obstructive hydroceph-
alus of the right ventricle, more pronounced effacement
of basilar cisterns, and compression on the brainstem
(Fig. 1D). Clinically, however, the patient’s confusion
and headache improved and she was discharged home
on prednisolone and fluconazole consolidation therapy.
The patient died unexpectedly a week later at home.
Post-mortem, a neurocysticercosis enzyme-linked immu-
noelectrotransfer blot (EITB) assay was positive for cysti-
cercosis on CSF but negative on serum. It was
performed in the Department of Clinical Parasitology,
Hospital for Tropical Diseases London.
Discussion and conclusion
This case demonstrates the difficulties of managing CM
in limited resource settings and the diagnostic challenges
encountered when a patient with known CM presents
with neurological deterioration late in the course of
treatment. These severely immunocompromised patients
are at risk of treatment failure and paradoxical immune
reconstitution inflammatory (IRIS) reactions. However,
they are also vulnerable to a range of other opportunistic
CNS infections that form important differential diagno-
ses when neurological deterioration is observed despite
effective treatment.
CM paradoxical IRIS is a key differential diagnosis. It
is suspected when a patient who initially responded to
antifungal therapy clinically deteriorates. The cause is an
exaggerated inflammatory response that occurs due to
the recovery of disease-specific immune response after
ART initiation. The incidence of CM paradoxical IRIS is
between 13 and 30% and tends to occur 1–2months
post ART initiatio n[5]. .Our patient presented with
neurological deterioration 28 days after commencement
of anti-fungal therapy and approximately 3 months after
starting ART. A diagnosis of paradoxical IRIS was con-
sidered, but was thought to be less likely because a re-
peat CD4 count did not suggest rapid immune
reconstitution, and CSF analysis showed no signs of in-
flammation [5].
Instead, the positive cryptococcal CSF culture
prompted us to treat for suspected cryptococcoma for-
mation with anti-fungal treatment escalation and pred-
nisolone. Cryptococcoma are granulomatous lesions that
form around a focal tissue infection of Cryptococcus
neoformans.
Typically, the formation of cryptococcoma depends on
an inflammatory response and are therefore more often
seen in immunocompetent individuals or those who
have initiated on ART. Case reports of cryptococcoma
have described patients who presented with persistent
neurological findings with sterile CSF or a low fungal
burden [6]. This is because the walled off mass is
thought to continuously shed Cryptococcus neoformans
into the CSF [6]. As with CM, the mainstay of treatment
is combination amphotericin-based antifungal agents.
Cysticercosis is a human parasitic infection caused by
larval cysts of the tapeworm Taenia solium. It is com-
monly found in rural areas of low and middle-income
countries with poor sanitation. Human ingestion of T.
solium eggs releases larvae which migrate from the intes-
tine, spread through the body via the bloodstream and
develop into cysts in a variety of sites. The most com-
mon sites include the muscles, eyes, brain, and spinal
cord. Presenting symptoms depend on the location, size,
number, and stage of the cyst [7]. According to commu-
nity based human prevalence studies, sero-prevalence of
human cysticercosis ranges from 7 to 22% in Africa [8].
Neurocysticercosis (NCC) manifests with nonspecific
symptoms and lack of diagnostic tests makes definitive
diagnosis particularly difficult in this setting. A system-
atic review of clinical manifestations of NCC found that
nearly 80% of patients with NCC had late onset seizures,
38% had headaches and 12% had raised intracranial
pressure [9]. Our patient had no history of seizures; the
subsequent headache, raised ICP and cognitive decline
was initially thought to be related to her CM. NCC was
considered as a possible diagnosis but given its relatively
low incidence rate of about 5.5% in the region [8], a de-
cision was made to treat our patient for CM associated
cryptococcoma while investigating her further.
Serological confirmation of NCC in HIV-infected indi-
viduals is problematic. We have found no robust ana-
lyses of serology in the context of HIV and NCC in the
literature. The positive CSF serology without detectable
serum antibody is unexplained. It could be due to local
antibody production in the context of insufficient anti-
gen exposure peripherally, however we have no evidence
for this.
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Brain imaging is not routinely available at presentation
for patients with meningitis due to financial constraints
in Malawi. It is, therefore, reserved for patients who de-
teriorate despite appropriate treatment or who develop
complications just like our patient. The imaging appear-
ance of the cystic lesions was consistent with a rare
extra-parenchymal form of NCC called racemose NCC.
This form derives its name from the grape-like appear-
ance of the confluent cysts on MRI which are located in
the basal subarachnoid spaces or the Sylvian fissure [10].
The confluent cysts result from excessive and unusual
growth of the cyst wall and development of vesicular le-
sions without scoleces. The primary effect of growth of
the racemose cysts is to cause intracranial hypertension
and hydrocephalus by obstructing the flow of CSF. This
makes prognosis worse except when neurosurgery is
available [10]. In our patient, the neuroimaging findings
of multiple cystic lesions without a discernable scolex
and asymmetrical early hydrocephalus, and the detected
cysticercal antibody fulfill two major neuroimaging and
one major clinical criteria consistent with a definitive
diagnosis of NCC according to the revised diagnostic
criteria for NCC [11].
Treatment of NCC involves anthelminthic treatment,
corticosteroids and management of complications like
seizures, headaches, and hydrocephalus. For parenchy-
mal NCC, randomized clinical trials have shown that use
of combined antiparasitic therapy with albendazole and
praziquantel increases the parasiticidal effect in patients
with multiple brain cysts without increased side effects,
but the trial did not include racemose NCC cases [12].
Patients with HIV-associated CM are profoundly im-
munocompromised and may have multiple pathologies
simultaneously. Given the paucity of access to neuroim-
aging facilities and serological assays in many African
countries, this condition may be more frequent than
generally thought. In endemic areas, clinicians should be
aware of neurocysticercosis and its unusual manifesta-
tions in HIV-infected patients. Where there is CNS de-
terioration despite effective therapy for CM or other
CNS opportunistic infections, neurocysticercosis should
be included in the differential diagnosis. Empirical treat-
ment without diagnostic brain imaging is not recom-
mended but symptom control with appropriate
anticonvulsant therapy is a priority. Corticosteroids in
addition to specific antiparasitic therapy may be neces-
sary where there is lesion associated edema on imaging.
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